Oslo (Norway), 11 January 2022 - PCI Biotech (OSE: PCIB), a cancer focused
biopharmaceutical company, today announced that results from preclinical studies
on tuberculosis performed in collaboration with The University of Zurich and ETH
Zurich are accepted for publication in Frontiers in Immunology, a high impact
immunology journal. The article title is "Photochemically-mediated inflammation
and cross-presentation of Mycobacterium bovis BCG proteins stimulates strong CD4
and CD8 T-cell responses in mice" and the abstract of the publication is
available through this link:
www.frontiersin.org/articles/10.3389/fimmu.2022.815609/abstract.

Anders Høgset, CSO of PCI Biotech, comments: "Infectious diseases are not within
PCI  Biotech's core focus areas, but  these positive results support our general
understanding  of fimaVacc's  mode of  action and  further demonstrate the broad
potential of the technology."

Contact information:
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech
PCI  Biotech  is  a  biopharmaceutical  late-stage  clinical development company
focusing  on  development  and  commercialisation  of  novel  therapies  for the
treatment  of cancer through its  innovative photochemical internalisation (PCI)
technology  platform.  PCI  is  applied  to three distinct anticancer paradigms:
fimaChem  (enhancement of chemotherapeutics for  localised treatment of cancer),
fimaVacc  (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical  internalisation induces triggered endosomal  release that is used
to  unlock the  true potential  of a  wide array  of therapeutic modalities. The
company's  lead  programme  fimaChem  consists  of  a pivotal study in bile duct
cancer,  an  orphan  indication  with  a  high  unmet  need and without approved
products.  fimaVacc applies  a unique  mode of  action to  enhance the essential
cytotoxic  effect of  therapeutic cancer  vaccines, which  works in synergy with
several  other state-of-the-art  vaccination technologies.  fimaNAc utilises the
endosomal  release to provide  intracellular delivery of  nucleic acids, such as
mRNA  and RNAi  therapeutics, thereby  addressing one  of the  major bottlenecks
facing this emerging and promising field.

For      further      information,      please     visit:     www.pcibiotech.com
(http://www.pcibiotech.com)

Forward-looking statements
This  announcement may contain forward-looking statements, which as such are not
historical  facts, but  are based  upon various  assumptions, many  of which are
based,  in  turn,  upon  further  assumptions.  These assumptions are inherently
subject  to  significant  known  and  unknown  risks,  uncertainties  and  other
important  factors. Such risks, uncertainties, contingencies and other important
factors  could cause  actual events  to differ  materially from the expectations
expressed  or implied in  this announcement by  such forward-looking statements.
PCI  Biotech disclaims  any obligation  to update  or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.